FDG PET/CT in Clinical Oncology

• PART ONE – DIAGNOSIS: Solitary pulmonary nodule/chest mass.- Unknown primary.- Unsuspected malignancy/second primary.- PART TWO – EXTENT OF DISEASE: Head & Neck.- Lung.- Breast.- Esophageal.- Colorectal.- Lymphoma.- Multiple Myeloma.- Gynecology.- Miscellaneous.- PART THREE – FOLLOW UP: Lung Ca.- Breast  Ca.- Pancreas Ca.- Colorectal Ca.- Lymphoma.- Multiple Myeloma.- Thyroid Gland.- Urologic.- Miscellaneous.- PART FOUR - EVALUATION OF RESPONSE: Lymphoma.- Multiple Mueloma.- Lung.- Gastrointestinal Tumors.- Breast.- Neuroendocrine Tumor.

From the reviews:“This book, intended for those seeking additional perspectives on the growing field of 18F-FDG PET/CT, uses a case-based design with teaching points. … this book will be a good guide for the nuclear medicine physician, and the authors are to be thanked for producing it.” (Hyo Jung Seo, The Journal of Nuclear Medicine, Vol. 54 (10), October, 2013)“The authors have done a creditable job putting together 100 cases that illustrate the breadth … of current PETCT use in oncology. Individuals already experienced in PETCT reporting will find several cases of interest and educational but this book is firmly aimed at newcomers, be they nuclear medicine physicians, radiologists or clinical oncologists, and succeeds in providing an illustrated overview of FDG PETCT in oncology.” (Chirag Patel, RAD Magazine, May, 2013)“This text, organized to reflect problems that physicians face in their daily practice, clearly demonstrates the pivotal role of FDG PET in diagnosis, staging and follow-up of patients with cancer. FDG PET/CT in Clinical Oncology is of interest mainly to residents in nuclear medicine and radiology, but it may also be of interest to practitioners working in diagnostic imaging and all clinicians who are interested in better understanding the questions that can be answered by FDG PET in daily clinical practice.” (Antonio Manna and Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 40, 2013)